Alternative treatment scheme of seminoma for carboplatin, etoposide and bleomycin (CEB)
DOI:
https://doi.org/10.26641/2307-5279.21.1.2017.150085Keywords:
testicular tumors, chemotherapy, treatmentAbstract
Testicular germ cell tumors are highly sensitive to the chemotherapy, the standard treatment for seminoma stages II–III is 3PEB/4PE, treatment is associated with acute and delayed toxicity. Results of treatment of 17 patients under the scheme CEB (carboplatin AUC=5, etoposide 100 mg/m2in 1–5 days and bleomycin 30 mg on day 2). 3 years OS and DFS after 4CEBis 94,1% and 88,2% respectively, with less toxicity (associated with cisplatin to carboplatin replacement and bleomycin dose reduction to 30 mg). Preliminary results of the treatment with scheme 4CEB seminoma stage II–III can be considered as an alternative to the standard scheme.References
Bajorin D.F. Randomized trial of etoposideand cisplatinvs. etoposideandcarboplatin in patients with good-risk germ cell tumors: A multi-institutional study / D.F. Bajorin, M.F. Sarosdy, D.G. Pfister [et al.] // J. Clin. Oncol. – 1993. – V. 11. – P. 598–606.
Horwich A. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germcell cancer: A Multi-institutional Medical Research Council / A. Horwich, D.T. Sleijfer, S.D. Fossa [et al.] // J. Clin. Oncol. – 1997. – V. 15. – P. 1844–1852.
Bokemeyer C. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors / C. Bokemeyer, O. Kohrmann, J. Tischler [et al.] // Ann. Oncol. – 1996. – V. 7. – P. 1015–1021.
Powles T. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis / T. Powles, D. Robinson, J. Shamash [et al.] // Ann. Oncol. – 2008. – V. 19. – P. 443–447.
Oliver R.T. Radiotherapy versus singledose carboplatin in adjuvant treatment of stage I seminoma: A randomized trial / R.T. Oliver, M.D. Mason, G.M. Mead [et al.] // Lancet. – 2005. – V. 366. – P. 293–300.
Horwich A. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin / A. Horwich, D.P. Dearnaley, G.M. Duchesne [et al.] // J. Clin. Oncol. – 1989. – V. 7. – P. 1150–1156.
Schmoll H.J. Single-agent carboplatinum for advanced seminoma. A phase II study / H.J. Schmoll, A. Harstrick, C. Bokemeyer [et al.] // Cancer. – 1993. – V. 72. – P. 237–243.
Horwich A. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party / A. Horwich, R.T. Oliver, P.M. Wilkinson [et al.] // Br. J. Cancer. – 2000. – V. 83. – P. 1623–1629.
Bokemeyer C. Metastatic seminoma treated with either single agent carboplatin or cisplatinbased combination chemotherapy: A pooled analysis of two randomized trials / C. Bokemeyer, C. Kollmannsberger, S. Stenning [et al.] // Br. J. Cancer. – 2004. – V. 91. – P. 683–687.
International Germ Cell Consensus Classification: Aprognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group // J. Clin. Oncol. – 1997. – V. 15. – P. 594–603.
Horwich A. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin / A. Horwich, D.P. Dearnaley, G.M. Duchesne [et al.] // J. Clin. Oncol. – 1989. – V. 7. – P. 150–156.
Schmoll H.J. Single-agent carboplatinum for advanced seminoma. A phase II study / H.J. Schmoll, A. Harstrick, C. Bokemeyer [et al.] // Cancer. – 1993. – V. 72. – P. 237–243.
Bokemeyer C. Metastatic seminoma treated with either single agent carboplatin or cisplatinbased combination chemotherapy: A pooled analysis of two randomized trials / C. Bokemeyer, C. Kollmannsberger, S. Stenning [et al.] // Br. J. Cancer. – 2004. – V. 91. – P. 683–687.
Bosl G.J. Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: A randomized comparison / G.J.Bosl, D.F. Bajorin // Semin. Oncol. – 1994. – V. 21. – P. 61–64.
Tjulandin S.A. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors / S.A. Tjulandin, A.M. Garin, A.A. Mescheryakov [et al.] // Ann. Oncol. – 1993. – V. 4. – P. 663–667.
Kondagunta G.V. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors / G.V. Kondagunta, J. Bacik, D. Bajorin [etal.] // J. Clin. Oncol. – 2005. – V. 23. – P. 9290–9294.
Downloads
Published
Issue
Section
License
Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).
Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.
